Late side effects of chemotherapy in ovarian carcinoma: a cytogenetic, hematologic, and statistical study.
Late side effects of chemotherapy were studied in 51 women who had received at least 300 mg of melphalan for ovarian cancer and had survived for at least three years. Hematologic, statistical, and cytogenetic methods were employed. Six cases of iatrogenic leukemia were found. They appeared to represent a hematologic entity that is fairly difficult to recognize. The risk of iatrogenic leukemia in women who survived for three years or more after melphalan treatment was calculated to be 950 times greater than the leukemia risk in the total female population. The cytogenetic changes were studied with three methods focused on sister chromatid exchange, chromosome aberrations, and DNA damage. The sister chromatid exchange frequency showed a marked increase, but it was corrected within a few months. Chromosome aberrations expressed by chromosome rearrangements were increased in the peripheral lymphocytes and may persist for several years. The frequency of DNA stand breaks was decreased indicating the presence of DNA cross-links. Any of these types of genetic alteration could be the initiating event in carcinogenesis.
D000208:Acute Disease; D000328:Adult; D000368:Aged; D001853:Bone Marrow / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007049:Iatrogenic Disease; D007938:Leukemia / Q000139:chemically induced / Q000473:pathology; D008558:Melphalan / Q000009:adverse effects*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012306:Risk; D012854:Sister Chromatid Exchange / Q000187:drug effects; D012907:Smoking
D008558:Melphalan